Aaron J Ciechanover

USPTO Granted Patents = 9 (Patent Applications = 2)

Average Co-Inventor Count = 5.1

ph-index = 3

Forward Citations = 25(Granted Patents)

Location History:

Haifa, IL (1995 - 2012)
Caesarea, IL (2022)

Company Filing History:

5 out of 169

Signal Pharmaceuticals, Inc.

patents

2 out of 34

Rappaport Family Institute for Research in the Medical Sciences

patents

2 out of 944

Technion Research & Development Foundation Limited

patents

4. 1 out of 891

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

patents

5. 1 out of 1

Rockefeller Institute

patent

where one patent can have more than one assignee

Years Active: 1995-2025

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12421510 - Peptide, a complex and a method for treating cancer (2025-09-23),

2. 11452759 - Ubiquitin ligase KPC1 promotes processing of P105 NF-κB1 to p50, eliciting strong tumor suppression (2022-09-27),

3. 8263326 - Compounds and methods for modulating activation of NF-κB (2012-09-11),

4. 7507788 - Peptides and methods for cell death regulation (2009-03-24),

5. 7414120 - Compounds and methods for modulating activation of NF-κB (2008-08-19),

6. 7186503 - Compounds and methods for modulating activation of NF-κB (2007-03-06),

7. 6656713 - Compounds and methods for modulating activation of NF-&kgr;B (2003-12-02),

8. 5932425 - Compositions and methods for modulating cellular NF-.kappa.B activation (1999-08-03),

9. 5384255 - Ubiquitin carrier enzyme E2-F1, purification, production, and use (1995-01-24),

Title: The Innovations of Aaron J Ciechanover

Introduction

Aaron J Ciechanover is a prominent inventor based in Haifa, Israel. He has made significant contributions to the field of cancer treatment through his innovative research and patented inventions. With a total of 9 patents, Ciechanover has established himself as a key figure in medical science.

Latest Patents

Ciechanover's latest patents include groundbreaking methods for treating cancer. One notable invention is a peptide comprising the amino acid sequence WILVRLW, which can be linked to molecules that recruit E3 ligase. This method aims to enhance cancer treatment efficacy. Another significant patent involves the ubiquitin ligase KPC1, which promotes the processing of P105 NF-κB1 to p50, thereby eliciting strong tumor suppression. This invention provides a method for administering KPC1 or p50 to treat cancer effectively.

Career Highlights

Throughout his career, Ciechanover has worked with various esteemed organizations. He has been associated with Signal Pharmaceuticals, Inc. and the Rappaport Family Institute for Research in the Medical Sciences. His work has focused on developing innovative solutions for complex medical challenges.

Collaborations

Ciechanover has collaborated with notable colleagues, including Anthony M Manning and Frank Mercurio. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Aaron J Ciechanover's contributions to cancer treatment through his patents and collaborations highlight his role as a leading inventor in the medical field. His innovative approaches continue to pave the way for advancements in cancer therapies.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

2 patents pending:

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.